Evidence map›Paper›PMID 15835751›Full record

ArticlePharmaceutical research2005

Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities.

Karsten Bucher, Camille A Besse, Sarah W Kamau, Heidi Wunderli-Allenspach, Stefanie D Krämer

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karsten BucherInstitute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH, Federal Institute of Technology, Zürich, Switzerland.
Camille A Besse
Sarah W Kamau
Heidi Wunderli-Allenspach
Stefanie D Krämer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeP-glycoprotein (P-gp), a membrane ATPase expelling many structurally unrelated compounds out of cells, is one of the major contributors to multidrug resistance. It is enriched in cold TritonX-100 insoluble membrane domains (i.e., rafts). The purpose of this work was to characterize the ATPase activities of raft preparations from P388 cells overexpressing P-gp (P388/ADR) or devoid of P-gp (P388) and to establish a P-gp-enriched screening system for P-gp-interfering compounds.

methodsRafts were extracted with cold TritonX-100. The ATPase activity was characterized in 96-well plates using a fluorescence assay.

resultsThe ATPase activity per mg protein was about five times higher in P388/ADR rafts than in crude membranes. The anti-P-gp antibody C219 inhibited 20% of the activity in P388/ADR rafts but only about 10% of the activity in P388/ADR crude membranes and had no effect on the activity of P388 rafts. The known P-gp-activating compounds verapamil, progesterone, and valinomycin revealed the typical bell-shaped activity/concentration profiles in P388/ADR rafts, indicative for activation at low compound concentrations and inhibition at concentrations >10 to 100 microM. The inhibitory effect was also observed in P388 rafts.

conclusionsExtracted rafts are rich in functional ATPases. Rafts from P-gp-overexpressing cells display P-gp-typical ATPase activity and provide an easy, P-gp-enriched screening system.

Indexed as

Adenosine TriphosphatasesAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1Dose-Response Relationship, DrugDoxorubicinDrug Resistance, NeoplasmEnzyme InhibitorsLeukemia P388Membrane MicrodomainsMiceAdenosine TriphosphatasesATP Binding Cassette Transporter, Subfamily B, Member 1DoxorubicinEnzyme Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.